市場調查報告書

骨質疏鬆症 - 市場洞察,流行病學,市場預測 2028年

Osteoporosis Market Insights, Epidemiology and Market Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 401911
出版日期 內容資訊 英文 180 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
骨質疏鬆症 - 市場洞察,流行病學,市場預測 2028年 Osteoporosis Market Insights, Epidemiology and Market Forecast - 2028
出版日期: 2019年12月01日內容資訊: 英文 180 Pages
簡介

本報告提供主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的骨質疏鬆症市場調查,總括性彙整疾病概要和現行的治療方法,新藥的簡介,主要7個國家的市場趨勢,流行病學的預測,市場規模,患病數·罹患數的變化與預測,未滿足需求,市場成長要素及障礙等資訊。

目錄

第1章 簡介

第2章 市場概要

  • 市場佔有率分析(實際成果值)
  • 市場佔有率分析(預測值)

第3章 疾病背景和概要:骨質疏鬆症

  • 簡介
  • 症狀
  • 病因
  • 危險因素
  • 病理學
  • 診斷
  • 治療

第4章 流行病學和患者人口

  • 主要調查結果
  • 主要7個國家骨質疏鬆症的整體罹患數·罹患數
  • 主要7個國家骨質疏鬆症的整體罹患患者數 - 各國

第5章 骨質疏鬆症的流行病學:各國

  • 美國
    • 假設和理論的根據
    • 骨質疏鬆症的整體患病數·罹患數
    • 骨質疏鬆症的病例數:各類型
    • 骨質疏鬆症的病例數:性別
    • 骨質疏鬆症的診斷數量
    • 骨質疏鬆症可治療的病例數
  • 歐盟5國
    • 假設和理論的根據
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第6章 現行治療

  • 治療流程
  • 治療指南

第7章 未滿足需求

第8章 已上市治療藥

  • 醫藥品 A
    • 醫藥品概要
    • 作用機制
    • 法規的里程碑
    • 優點與缺點
    • 產品簡介
  • 醫藥品 B

第9章 開發平台治療藥

第10章 主要交叉對比

第11章 新藥

  • 醫藥品 C
    • 醫藥品概要
    • 臨床試驗詳細內容
    • 安全性和有效性
    • 優點與缺點
    • 開發平台開發趨勢
    • 產品簡介
  • 醫藥品 D

第12章 骨質疏鬆症:主要7個國家的市場分析

  • 市場規模
  • 已上市治療藥的市場佔有率
  • 治療藥的銷售量:各產品

第13章 骨質疏鬆症:各國市場分析

  • 美國
    • 市場規模
    • 已上市治療藥的市場佔有率
    • 治療藥的銷售量:各產品
    • 新藥及其對市場的影響
  • 歐盟5國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第14章 市場成長要素

第15章 市場障礙

第16章 附錄

第17章 調查手法

  • 出處

第18章 DelveInsight的服務內容

第19章 免責聲明

第20章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0330

DelveInsight's 'Osteoporosis-Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Osteoporosis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Osteoporosis from 2017 to 2028 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028

Osteoporosis - Disease Understanding and Treatment Algorithm

Osteoporosis is defined as a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. Osteoporosis is a bone disorder that increases a person's risk of fracture due to low bone mineral density (BMD), impaired bone microarchitecture/mineralization, and/or decreased bone strength. Although osteoporosis is typically associated with women, it is also diagnosed in men, who account for an estimated one in five Americans who have osteoporosis or low bone mineral density (BMD). In addition to being the major cause of fractures in the older population, osteoporosis is also highly associated with people becoming bedridden, which can lead to serious complications. Osteoporosis can be divided into primary and secondary osteoporosis, wherein primary occurs with age and sex hormone deficiency and secondary osteoporosis occurs with several comorbid diseases and medications.

Osteoporosis can be diagnosed with a BMD test, bone mineral density (BMD) test, Fracture Risk Assessment Tool Model (FRAX), Vertebral imaging (Vertebral fracture assessment), Biochemical bone turnover marker (BTM), Quantitative Ultrasound (QUS), Quantitative Computed Tomography (QCT) and Peripheral QCT (pQCT) and Quality of DXA AND VFA. BMD tests can identify osteoporosis, determine the risk for fractures (broken bones), and measure response to osteoporosis treatment. The most widely recognized BMD test is a central dual-energy x-ray absorptiometry or central DXA test. Treatment of osteoporosis is strictly related to the severity of pathology. Initially, it is important to prevent fragility fractures with an active lifestyle and adequate nutritional supplements, including daily calcium and vitamin D intake, performing weight-bearing activities, avoiding or stopping smoking, and avoiding heavy alcohol consumption.

The DelveInsight Osteoporosis market report gives the thorough understanding of Osteoporosis by including details such as disease introduction, types of osteoporosis, causes of osteoporosis, symptoms, pathophysiology, pathology, risk factors, diagnosis, diagnostic biomarkers and differential diagnosis.

Osteoporosis Epidemiology

According to the International Osteoporosis Foundation (IOF), around the world, one in three women and one in five men aged fifty years and over are at risk of an osteoporotic fracture. In fact, an osteoporotic fracture is estimated to occur every 3 s. The most common fractures associated with osteoporosis occur at the hip, spine, and wrist. The likelihood of these fractures occurring, particularly at the hip and spine, increases with age in both women and men. IOF estimate that over 44 million people in the United States currently have osteoporosis. Approximately 30% of all postmenopausal women have osteoporosis in the United States and Europe. At least 40% of these women and 15-30% of men will sustain one or more fragility fractures in their remaining lifetime. An increased risk of 86% for any fracture has been demonstrated in people that have already sustained a fracture. Likewise, patients with a history of vertebral fracture have a 2.3-fold increased risk of future hip fracture and a 1.4-fold increase in the risk of distal forearm fracture.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Osteoporosis in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028 for the following aspects:

The disease epidemiology covered in the report is segmented by:

  • Prevalence of Osteoporosis
  • Diagnosed Prevalent Population of Osteoporosis
  • Gender-specific Prevalence of Osteoporosis
  • Prevalence of Primary Osteoporosis
  • Prevalence of Secondary Osteoporosis
  • Incidence of Osteoporotic Fractures
  • Osteoporosis-related comorbidities

As per a study conducted by Rausch et al. titled "We miss the opportunity: Pretreatment of osteoporosis in a German trauma center," in Germany, the prevalence for osteoporosis in individuals of age 50 and above is estimated to be around 26% overall and 39% in women. In males, prevalence is estimated to be on a significantly lower level with 9.7% of the population over 50 years. Approximately 399 patients >60 years suffering low-energy-fractures of their spine, femur, humerus or forearm between 2014 and 2015 were recruited in a German trauma center. In about 21% (84 out of 399) of all patients, osteoporosis was diagnosed prior to current admission. Nearly 34% (136 out of 399) suffered a prior risk-fracture after age of 50. Also, 38% (19 out of 50) of these patients with fragility fractures and prior osteoporosis diagnosis received anti-osteoporotic medication. In case of corticoids taken by the patients, about 15.4% and 13.3% resulted in osteoporosis with prior and no prior fracture, respectively.

A clinical review study by the US Preventive Services Task Force Recommendation Statement projected that by 2020, approximately 12.3 million individuals in the United States older than 50 years are expected to have osteoporosis. Osteoporotic fractures, particularly hip fractures, are associated with limitations in ambulation, chronic pain and disability, loss of independence, and decreased quality of life, and 21-30% of patients who experience a hip fracture die within 1 year.

Osteoporosis Drug Chapters

This segment of the Osteoporosis report encloses the detailed analysis of the drugs that are expected to be launched in other regions. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the prevalent population of Osteoporosis and awareness of the disease. The overall dynamics of Osteoporosis market is anticipated to change in the coming years owing to the expected launch of emerging therapies that are already approved in specific regions but are expected to be launched in other regions as well. The major key players such as Amgen, Radius Health, and others will significantly increase the market during the forecast period (2019-2028).

Osteoporosis Market Outlook

Osteoporosis is a metabolic bone disease characterized by an imbalance between bone resorption and accrual, resulting in microarchitectural disruption, reduced bone mineral density (BMD), and skeletal fragility. Fragility fractures are common in the osteoporotic population and occur from forces, not ordinarily resulting in fracture. The most common sites are the vertebral column, hip and wrist; however, fragility fractures of the humerus, pelvis and ribs are not uncommon.

The treatment for Osteoporosis majorly includes pharmacological therapies to reduce the risk of fractures. Medications to treat osteoporosis are categorized as either antiresorptive (i.e., bisphosphonates, estrogen agonist/antagonists (EAAs), estrogens, calcitonin, and denosumab) or anabolic (i.e., teriparatide). Bisphosphonates are therefore effective agents to increase bone mineral density (BMD) at the spine and hip when used as primary prevention or as treatment in both men and women on long-term glucocorticoids.

The treatment of Osteoporosis mainly follows a mainstay treatment, i.e., pharmacological agents (bisphosphonates, hormone replacement therapy, selective estrogen receptor modulators, calcitonin, the 1-34 fragment of parathyroid hormone), calcium and vitamin D supplements, and calcitriol followed by surgery which is only preferred in case of severe osteoporosis cases in patients.

This segment gives a through detail of market trend of each therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Osteoporosis in the 7MM is expected to change from 2019-2028.

Osteoporosis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Approval of therapies for Osteoporosis such as Evenity (Amgen; to be launched in Europe), Tymlos (Radius Health; to be launched in Europe), and other targeted therapies in the forecast period [2019-2028] will also create a positive impact on the Osteoporosis market.

Osteoporosis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Osteoporosis Report Key Strengths

  • 10-Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Osteoporosis Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Osteoporosis market
  • Organize sales and marketing efforts by identifying the best opportunities for Osteoporosis market
  • To understand the future market competition in the Osteoporosis market.

Note: We understand the needs of the rapidly changing market and DelveInsight's is helping the client by providing the most up to date Report. It usually takes 7-10 days to deliver this kind of Report.

Table of Contents

1. Key Insights

  • 1.1. Market Share (%) Distribution of Osteoporosis in 2017
  • 1.2. Market Share (%) Distribution of Osteoporosis in 2028

2. Disease Background and Overview: Osteoporosis

  • 2.1. Introduction
  • 2.2. Types of osteoporosis
    • 2.2.1. Primary osteoporosis
    • 2.2.2. Secondary Osteoporosis
    • 2.2.3. Glucocorticoid-Induced Osteoporosis
  • 2.3. Causes of Osteoporosis
  • 2.4. Symptoms
  • 2.5. Pathophysiology of Osteoporosis
    • 2.5.1. Architectural composition: cortical versus cancellous bone
    • 2.5.2. Molecular composition: mineralized versus nonmineralized components
    • 2.5.3. Cellular control of bone mass: osteoblasts and osteoclasts
    • 2.5.4. Circulating factors that influence bone cell function
    • 2.5.5. Age-related bone loss and osteoporosis
    • 2.5.6. Geometry: effects of osteoporosis on cancellous bone
    • 2.5.7. Geometry: effects of osteoporosis on cortical bone
    • 2.5.8. Geometry: effects on vertebral body strength
  • 2.6. Pathology of Osteoporosis
    • 2.6.1. Factors That Affect Bone Quantity and Quality
    • 2.6.2. Bone Remodeling and its Relationship to Bone Quantity
  • 2.7. Risk Factors for Osteoporosis
  • 2.8. Diagnosis of osteoporosis
    • 2.8.1. Fracture Risk Assessment Tool Model (FRAX)
    • 2.8.2. Vertebral imaging (Vertebral fracture assessment)
    • 2.8.3. Biochemical bone turnover marker (BTM)
    • 2.8.4. Dual-Energy X-Ray Absorptiometry (DXA)
    • 2.8.5. Quantitative Ultrasound (QUS)
    • 2.8.6. Quantitative Computed Tomography (QCT) and Peripheral QCT (pQCT)
    • 2.8.7. Quality of DXA AND VFA
  • 2.9. Diagnostic Biomarkers of Osteoporosis
    • 2.9.1. miR-21 and miR-148a
    • 2.9.2. miR-31 and miR-194
    • 2.9.3. miR-133a and miR-27
    • 2.9.4. miR-30b and miR-142
  • 2.10. Differential diagnosis
  • 2.11. Diagnostic Algorithm
  • 2.12. European Guidelines for diagnosis of Osteoporosis in postmenopausal women
    • 2.12.1. Diagnosis of osteoporosis
    • 2.12.2. Assessment of fracture risk
  • 2.13. Diagnostic guidelines from the Italian Society for Orthopedics and Traumatology
    • 2.13.1. Diagnosis of osteoporosis

3. Recognized Establishments

    • 3.1.1. United States
    • 3.1.2. Europe
    • 3.1.3. Japan

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. 7MM Countries Total Diagnosed Incident Patient Population of Osteoporosis

5. Country Wise-Epidemiology of Osteoporosis

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Osteoporosis Prevalence in the United States
    • 5.1.3. Osteoporosis Diagnosed Prevalent Population in the United States
    • 5.1.4. Osteoporosis Gender-specific Prevalence in the United States
    • 5.1.5. Primary Osteoporosis Prevalence in the United States
    • 5.1.6. Secondary Osteoporosis Prevalence in the United States
    • 5.1.7. Osteoporotic Fractures Incidence in the United States
    • 5.1.8. Osteoporosis-related comorbidities in the United States
  • 5.2. EU5 Countries
    • 5.2.1. Assumptions and Rationale
    • 5.2.2. Germany
    • 5.2.3. France
    • 5.2.4. Italy
    • 5.2.5. Spain
    • 5.2.6. United Kingdom
  • 5.3. Germany
    • 5.3.1. Osteoporosis Prevalence in Germany
    • 5.3.2. Osteoporosis Diagnosed Prevalent Population in Germany
    • 5.3.3. Osteoporosis Gender-specific Prevalence in Germany
    • 5.3.4. Primary Osteoporosis Prevalence in Germany
    • 5.3.5. Secondary Osteoporosis Prevalence in Germany
    • 5.3.6. Osteoporotic Fractures Incidence in Germany
    • 5.3.7. Osteoporosis-related comorbidities in Germany
  • 5.4. France
    • 5.4.1. Osteoporosis Prevalence in France
    • 5.4.2. Osteoporosis Diagnosed Prevalent Population in France
    • 5.4.3. Osteoporosis Gender-specific Prevalence in France
    • 5.4.4. Primary Osteoporosis Prevalence in France
    • 5.4.5. Secondary Osteoporosis Prevalence in France
    • 5.4.6. Osteoporotic Fractures Incidence in France
    • 5.4.7. Osteoporosis-related comorbidities in France
  • 5.5. Italy
    • 5.5.1. Osteoporosis Prevalence in Italy
    • 5.5.2. Osteoporosis Diagnosed Prevalent Population in Italy
    • 5.5.3. Osteoporosis Gender-specific Prevalence in Italy
    • 5.5.4. Primary Osteoporosis Prevalence in Italy
    • 5.5.5. Secondary Osteoporosis Prevalence in Italy
    • 5.5.6. Osteoporotic Fractures Incidence in Italy
    • 5.5.7. Osteoporosis-related comorbidities in Italy
  • 5.6. Spain
    • 5.6.1. Osteoporosis Prevalence in Spain
    • 5.6.2. Osteoporosis Diagnosed Prevalent Population in Spain
    • 5.6.3. Osteoporosis Gender-specific Prevalence in Spain
    • 5.6.4. Primary Osteoporosis Prevalence in Spain
    • 5.6.5. Secondary Osteoporosis Prevalence in Spain
    • 5.6.6. Osteoporotic Fractures Incidence in Spain
    • 5.6.7. Osteoporosis-related comorbidities in Spain
  • 5.7. United Kingdom
    • 5.7.1. Osteoporosis Prevalence in the United Kingdom
    • 5.7.2. Osteoporosis Diagnosed Prevalent Population in the United Kingdom
    • 5.7.3. Osteoporosis Gender-specific Prevalence in the United Kingdom
    • 5.7.4. Primary Osteoporosis Prevalence in the United Kingdom
    • 5.7.5. Secondary Osteoporosis Prevalence in the United Kingdom
    • 5.7.6. Osteoporotic Fractures Incidence in the United Kingdom
    • 5.7.7. Osteoporosis-related comorbidities in the United Kingdom
  • 5.8. Japan
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Osteoporosis Prevalence in Japan
    • 5.8.3. Osteoporosis Diagnosed Prevalent Population in Japan
    • 5.8.4. Osteoporosis Gender-specific Prevalence in Japan
    • 5.8.5. Primary Osteoporosis Prevalence in Japan
    • 5.8.6. Secondary Osteoporosis Prevalence in Japan
    • 5.8.7. Osteoporotic Fractures Incidence in Japan
    • 5.8.8. Osteoporosis-related comorbidities in Japan

6. Treatment

  • 6.1. Pharmacological Treatment
    • 6.1.1. Antiresorptive Agents
    • 6.1.2. Anabolic Agents
    • 6.1.3. Mixed Agent
  • 6.2. Dietary Supplements
    • 6.2.1. Calcium
    • 6.2.2. Vitamin D
  • 6.3. Surgery
    • 6.3.1. Kyphoplasty
    • 6.3.2. Vertebroplasty
  • 6.4. Treatment Algorithm

7. Endocrine Society: 2019

8. National Osteoporosis Guideline Group (NOGG): 2018

  • 8.1. Osteoporosis in men

9. American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis: 2017

    • 9.1.1. Recommendations for fracture risk assessment and reassessment
    • 9.1.2. Recommendations for initial treatment for prevention of GIOP in special populations of patients beginning long-term GC treatment

10. American College of Physicians (ACP): 2017

11. Unmet Needs

12. Marketed Drugs

  • 12.1. Marketed Drugs Key-cross Competition
  • 12.2. Evenity (romosozumab-aqqg): Amgen
    • 12.2.1. Drug Description
    • 12.2.2. Regulatory Milestones
    • 12.2.3. Other Development Activities
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile
  • 12.3. Prolia (Denosumab): Amgen
    • 12.3.1. Drug Description
    • 12.3.2. Regulatory Milestone
    • 12.3.3. Other Developmental Activities
    • 12.3.4. Safety and Efficacy
    • 12.3.5. Current Pipeline Activity
    • 12.3.6. Product Profile
  • 12.4. Fablyn (Lasofoxifene): Pfizer
    • 12.4.1. Drug Description
    • 12.4.2. Regulatory Milestone
    • 12.4.3. Other Developmental Activities
    • 12.4.4. Safety and Efficacy
    • 12.4.5. Product Profile
  • 12.5. Duavee (conjugated estrogens/bazedoxifene): Pfizer
    • 12.5.1. Drug Description
    • 12.5.2. Regulatory Milestones
    • 12.5.3. Other Development Activities
    • 12.5.4. Safety and Efficacy
    • 12.5.5. Product Profile
  • 12.6. Tymlos (abaloparatide): Radius Health
    • 12.6.1. Drug Description
    • 12.6.2. Regulatory Milestones
    • 12.6.3. Other Development Activities
    • 12.6.4. Safety and Efficacy
    • 12.6.5. Current Pipeline Activity
    • 12.6.6. Product Profile
  • 12.7. Bijuva (estradiol and progesterone): Therapeutics MD
    • 12.7.1. Drug Description
    • 12.7.2. Regulatory Milestones
    • 12.7.3. Other Development Activities
    • 12.7.4. Safety and Efficacy
    • 12.7.5. Product Profile
  • 12.8. Boniva (ibandronate sodium): Roche
    • 12.8.1. Drug Description
    • 12.8.2. Regulatory Milestones
    • 12.8.3. Other Development Activities
    • 12.8.4. Safety and Efficacy
    • 12.8.5. Product Profile
  • 12.9. Reclast (zoledronic acid): Novartis Pharmaceuticals
    • 12.9.1. Drug Description
    • 12.9.2. Regulatory Milestone
    • 12.9.3. Other Developmental Activities
    • 12.9.4. Safety and Efficacy
    • 12.9.5. Current Pipeline Activity
    • 12.9.6. Product Profile
  • 12.10. Forteo/Forsteo (Teriparatide): Eli Lilly
    • 12.10.1. Drug Description
    • 12.10.2. Regulatory Milestones
    • 12.10.3. Other Developmental Activities
    • 12.10.4. Safety and Efficacy
    • 12.10.5. Product Profile
  • 12.11. Bonsity (PF708): Pfenex
    • 12.11.1. Drug Description
    • 12.11.2. Regulatory Milestones
    • 12.11.3. Other Developmental Activities
    • 12.11.4. Safety and Efficacy
    • 12.11.5. Product Profile

13. Emerging Drugs

  • 13.1. Key Cross Competition
  • 13.2. Alendronate/Zoledronic Acid: Amgen
    • 13.2.1. Product Description
    • 13.2.2. Clinical Development
    • 13.2.3. Product Profile
  • 13.3. Denosumab/Teriparatide: Amgen
    • 13.3.1. Product Description
    • 13.3.2. Clinical Development
    • 13.3.3. Product Profile
  • 13.4. NaQuinate (Osteopura): Haoma Medica
    • 13.4.1. Product Description
    • 13.4.2. Other Developmental Activities
    • 13.4.3. Clinical Development
    • 13.4.4. Product Profile

14. What Experts Say?

15. Osteoporosis: 7 Major Market Analysis

  • 15.1. Key Findings
  • 15.2. Market Size of Osteoporosis in the 7MM

16. The United States Market Outlook

  • 16.1. United States
    • 16.1.1. Total Market size of Osteoporosis
    • 16.1.2. Current Market Size by Therapies

17. EU-5 Countries: Market Outlook

  • 17.1. Germany
    • 17.1.1. Total Market size of Osteoporosis
    • 17.1.2. Current Market Size by Therapies
  • 17.2. France
    • 17.2.1. Total Market size of Osteoporosis
    • 17.2.2. Current Market Size by Therapies
  • 17.3. Italy
    • 17.3.1. Total Market Size of Osteoporosis
    • 17.3.2. Current Market Size by Therapies
  • 17.4. Spain
    • 17.4.1. Total Market Size of Osteoporosis
    • 17.4.2. Current Market Size by Therapies
  • 17.5. United Kingdom
    • 17.5.1. Total Market Size of Osteoporosis
    • 17.5.2. Current Market Size by Therapies

18. Japan: Market Outlook

  • 18.1. Japan market Size
    • 18.1.1. Total Market Size of Osteoporosis
    • 18.1.2. Market Size by Therapies

19. Case Reports

  • 19.1. Postmenopausal Osteoporosis: The Role of Lifestyle in Maintaining Bone Mass and Reducing Fracture Risk
  • 19.2. A Case of Male Osteoporosis: A 37-Year-Old Man with Multiple Vertebral Compression Fractures
  • 19.3. Unexpected rapid increase in bone mineral density by bisphosphonate therapy after multiple spinal fractures

20. Market Drivers

21. Market Barriers

22. Appendix

  • 22.1. Report Methodology

23. DelveInsight Capabilities

24. Disclaimer

25. About DelveInsight

List of Tables

  • Table 1: WHO definitions of osteoporosis based on BMD
  • Table 2: Differential Diagnosis
  • Table 3: Total Diagnosed Prevalent Population of Osteoporosis in the 7MM Countries (2017-2028)
  • Table 4: Osteoporosis Prevalence in the United States (2017-2028)
  • Table 5: Osteoporosis Diagnosed Prevalent Population in the United States (2017-2028)
  • Table 6: Osteoporosis Gender-specific Prevalence in the United States (2017-2028)
  • Table 7: Primary Osteoporosis Prevalence in the United States (2017-2028)
  • Table 8: Secondary Osteoporosis Prevalence in the United States (2017-2028)
  • Table 9: Osteoporotic Fractures Incidence in the United States (2017-2028)
  • Table 10: Osteoporosis-related comorbidities in the United States (2017-2028)
  • Table 11: Osteoporosis Prevalence in Germany (2017-2028)
  • Table 12: Osteoporosis Diagnosed Prevalent Population in Germany (2017-2028)
  • Table 13: Osteoporosis Gender-specific Prevalence in Germany (2017-2028)
  • Table 14: Primary Osteoporosis Prevalence in Germany (2017-2028)
  • Table 15: Secondary Osteoporosis Prevalence in Germany (2017-2028)
  • Table 16: Osteoporotic Fractures Incidence in Germany (2017-2028)
  • Table 17: Osteoporosis-related comorbidities in Germany (2017-2028)
  • Table 18: Osteoporosis Prevalence in France (2017-2028)
  • Table 19: Osteoporosis Diagnosed Prevalent Population in France (2017-2028)
  • Table 20: Osteoporosis Gender-specific Prevalence in France (2017-2028)
  • Table 21: Primary Osteoporosis Prevalence in France (2017-2028)
  • Table 22: Secondary Osteoporosis Prevalence in France (2017-2028)
  • Table 23: Osteoporotic Fractures Incidence in France (2017-2028)
  • Table 24: Osteoporosis-related comorbidities in France (2017-2028)
  • Table 25: Osteoporosis Prevalence in Italy (2017-2028)
  • Table 26: Osteoporosis Diagnosed Prevalent Population in Italy (2017-2028)
  • Table 27: Osteoporosis Gender-specific Prevalence in Italy (2017-2028)
  • Table 28: Primary Osteoporosis Prevalence in Italy (2017-2028)
  • Table 29: Secondary Osteoporosis Prevalence in Italy (2017-2028)
  • Table 30: Osteoporotic Fractures Incidence in Italy (2017-2028)
  • Table 31: Osteoporosis-related comorbidities in Italy (2017-2028)
  • Table 32: Osteoporosis Prevalence in Spain (2017-2028)
  • Table 33: Osteoporosis Diagnosed Prevalent Population in Spain (2017-2028)
  • Table 34: Osteoporosis Gender-specific Prevalence in Spain (2017-2028)
  • Table 35: Primary Osteoporosis Prevalence in Spain (2017-2028)
  • Table 36: Secondary Osteoporosis Prevalence in Spain (2017-2028)
  • Table 37: Osteoporotic Fractures Incidence in Spain (2017-2028)
  • Table 38: Osteoporosis-related comorbidities in Spain (2017-2028)
  • Table 39: Osteoporosis Prevalence in the United Kingdom (2017-2028)
  • Table 40: Osteoporosis Diagnosed Prevalent Population in the United Kingdom (2017-2028)
  • Table 41: Osteoporosis Gender-specific Prevalence in the United Kingdom (2017-2028)
  • Table 42: Primary Osteoporosis Prevalence in the United Kingdom (2017-2028)
  • Table 43: Secondary Osteoporosis Prevalence in the United Kingdom (2017-2028)
  • Table 44: Osteoporotic Fractures Incidence in the United Kingdom (2017-2028)
  • Table 45: Osteoporosis-related comorbidities in the United Kingdom (2017-2028)
  • Table 46: Osteoporosis Prevalence in Japan (2017-2028)
  • Table 47: Osteoporosis Diagnosed Prevalent Population in Japan (2017-2028)
  • Table 48: Osteoporosis Gender-specific Prevalence in Japan (2017-2028)
  • Table 49: Primary Osteoporosis Prevalence in Japan (2017-2028)
  • Table 50: Secondary Osteoporosis Prevalence in Japan (2017-2028)
  • Table 51: Osteoporotic Fractures Incidence in Japan (2017-2028)
  • Table 52: Osteoporosis-related comorbidities in Japan (2017-2028)
  • Table 53: Comparison of Marketed Drugs
  • Table 54: Comparison of Emerging Drugs
  • Table 55: Alendronate/Zoledronic Acid, Clinical Trial Description
  • Table 56: NaQuinate, Clinical Trial Description
  • Table 57: 7 Major Market Size of Osteoporosis in USD Million (2017-2028)
  • Table 58: United States Market Size of Osteoporosis, USD Million (2017-2028)
  • Table 59: Market size of Osteoporosis by therapies in the United States, in USD Million (2017-2028)
  • Table 60: Market Size of Osteoporosis in Germany, in USD Million (2017-2028)
  • Table 61: Market size of Osteoporosis by therapies in Germany, in USD Million (2017-2028)
  • Table 62: Market Size of Osteoporosis in France, in USD Million (2017-2028)
  • Table 63: Market size of Osteoporosis by therapies in France, in USD Million (2017-2028)
  • Table 64: Market Size of Osteoporosis in Italy, in USD Million (2017-2028)
  • Table 65: Market size of Osteoporosis by therapies in Italy, in USD Million (2017-2028)
  • Table 66: Market Size of Osteoporosis in Spain, in USD Million (2017-2028)
  • Table 67: Market size of Osteoporosis by therapies in Spain, in USD Million (2017-2028)
  • Table 68: Market Size of Osteoporosis in the UK, in USD Million (2017-2028)
  • Table 69: Market size of Osteoporosis by therapies in the United Kingdom, in USD Million (2017-2028)
  • Table 70: Market Size of Osteoporosis in Japan, in USD Million (2017-2028)
  • Table 71: Market size of Osteoporosis by therapies in Japan, in USD Million (2017-2028)

List of Figures

  • Figure 1: Normal bone vs. osteoporotic bone
  • Figure 2: Overview of the mechanisms of glucocorticoid-induced osteoporosis (GCOP).
  • Figure 3: Causes of osteoporosis
  • Figure 4: Symptoms of osteoporosis
  • Figure 5: Normal bone showing good connectivity as compared to osteoporotic bone showing poor conductivity.
  • Figure 6: Basic types of stresses that the bone endures
  • Figure 7: The pathogenesis of osteoporosis-related fractures
  • Figure 8: The bone remodeling cycle.
  • Figure 9: Suggested role of FRAX in the assessment of fracture risk
  • Figure 10: Circulating miRNAs differentially expressed in osteoporotic patients, either upregulated (roman) or downregulated (italic), and their functions studied in bone cells.
  • Figure 11: Suggested algorithm for diagnosis and management of postmenopausal osteoporosis.
  • Figure 12: Total Diagnosed Prevalent Patient Population of Osteoporosis in the 7MM Countries (2017-2028)
  • Figure 13: Osteoporosis Prevalence in the United States (2017-2028)
  • Figure 14: Osteoporosis Diagnosed Prevalent Population in the United States (2017-2028)
  • Figure 15: Osteoporosis Gender-specific Prevalence in the United States (2017-2028)
  • Figure 16: Primary Osteoporosis Prevalence in the United States (2017-2028)
  • Figure 17: Secondary Osteoporosis Prevalence in the United States (2017-2028)
  • Figure 18: Osteoporotic Fractures Incidence in the United States (2017-2028)
  • Figure 19: Osteoporosis-related comorbidities in the United States (2017-2028)
  • Figure 20: Osteoporosis Prevalence in Germany (2017-2028)
  • Figure 21: Osteoporosis Diagnosed Prevalent Population in Germany (2017-2028)
  • Figure 22: Osteoporosis Gender-specific Prevalence in Germany (2017-2028)
  • Figure 23: Primary Osteoporosis Prevalence in Germany (2017-2028)
  • Figure 24: Secondary Osteoporosis Prevalence in Germany (2017-2028)
  • Figure 25: Osteoporotic Fractures Incidence in Germany (2017-2028)
  • Figure 26: Osteoporosis-related comorbidities in Germany (2017-2028)
  • Figure 27: Osteoporosis Prevalence in France (2017-2028)
  • Figure 28: Osteoporosis Diagnosed Prevalent Population in France (2017-2028)
  • Figure 29: Osteoporosis Gender-specific Prevalence in France (2017-2028)
  • Figure 30: Primary Osteoporosis Prevalence in France (2017-2028)
  • Figure 31: Secondary Osteoporosis Prevalence in France (2017-2028)
  • Figure 32: Osteoporotic Fractures Incidence in France (2017-2028)
  • Figure 33: Osteoporosis-related comorbidities in France (2017-2028)
  • Figure 34: Osteoporosis Prevalence in Italy (2017-2028)
  • Figure 35: Osteoporosis Diagnosed Prevalent Population in Italy (2017-2028)
  • Figure 36: Osteoporosis Gender-specific Prevalence in Italy (2017-2028)
  • Figure 37: Primary Osteoporosis Prevalence in Italy (2017-2028)
  • Figure 38: Secondary Osteoporosis Prevalence in Italy (2017-2028)
  • Figure 39: Osteoporotic Fractures Incidence in Italy (2017-2028)
  • Figure 40: Osteoporosis-related comorbidities in Italy (2017-2028)
  • Figure 41: Osteoporosis Prevalence in Spain (2017-2028)
  • Figure 42: Osteoporosis Diagnosed Prevalent Population in Spain (2017-2028)
  • Figure 43: Osteoporosis Gender-specific Prevalence in Spain (2017-2028)
  • Figure 44: Primary Osteoporosis Prevalence in Spain (2017-2028)
  • Figure 45: Secondary Osteoporosis Prevalence in Spain (2017-2028)
  • Figure 46: Osteoporotic Fractures Incidence in Spain (2017-2028)
  • Figure 47: Osteoporosis-related comorbidities in Spain (2017-2028)
  • Figure 48: Osteoporosis Prevalence in the United Kingdom (2017-2028)
  • Figure 49: Osteoporosis Diagnosed Prevalent Population in the United Kingdom (2017-2028)
  • Figure 50: Osteoporosis Gender-specific Prevalence in the United Kingdom (2017-2028)
  • Figure 51: Primary Osteoporosis Prevalence in the United Kingdom (2017-2028)
  • Figure 52: Secondary Osteoporosis Prevalence in the United Kingdom (2017-2028)
  • Figure 53: Osteoporotic Fractures Incidence in the United Kingdom (2017-2028)
  • Figure 54: Osteoporosis-related comorbidities in the United Kingdom (2017-2028)
  • Figure 55: Osteoporosis Prevalence in Japan (2017-2028)
  • Figure 56: Osteoporosis Diagnosed Prevalent Population in Japan (2017-2028)
  • Figure 57: Osteoporosis Gender-specific Prevalence in Japan (2017-2028)
  • Figure 58: Primary Osteoporosis Prevalence in Japan (2017-2028)
  • Figure 59: Secondary Osteoporosis Prevalence in Japan (2017-2028)
  • Figure 60: Osteoporotic Fractures Incidence in Japan (2017-2028)
  • Figure 61: Osteoporosis-related comorbidities in Japan (2017-2028)
  • Figure 62: Treatment Algorithm for Osteoporosis
  • Figure 63: Treatment algorithm modified from Scottish Intercollegiate Guidelines Network, 2015
  • Figure 64: Algorithm for monitoring of long-term bisphosphonate therapy in postmenopausal women.
  • Figure 65: Unmet Needs of osteoporosis
  • Figure 66: 7 Major Market Size of Osteoporosis in USD Million (2017-2028)
  • Figure 67: Market Size of Osteoporosis in the United States, USD Millions (2017-2028)
  • Figure 68: Market size of Osteoporosis by therapies in the US, in USD Million (2017-2028)
  • Figure 69: Market Size of Osteoporosis in Germany, USD Million (2017-2028)
  • Figure 70: Market Size of Osteoporosis by therapies, in Germany, in USD Million (2017-2028)
  • Figure 71: Market Size of Osteoporosis in France, USD Million (2017-2028)
  • Figure 72: Market Size of Osteoporosis by therapies, in France, in USD Million (2017-2028)
  • Figure 73: Market Size of Osteoporosis in Italy, USD Million (2017-2028)
  • Figure 74: Market Size of Osteoporosis by therapies, in Italy, in USD Million (2017-2028)
  • Figure 75: Market Size of Osteoporosis in Spain, USD Million (2017-2028)
  • Figure 76: Market Size of Osteoporosis by therapies in Spain, in USD Million (2017-2028)
  • Figure 77: Market Size of Osteoporosis in the UK, USD Million (2017-2028)
  • Figure 78: Market Size of Osteoporosis by therapies in the UK, in USD Million (2017-2028)
  • Figure 79: Market Size of Osteoporosis in Japan, USD Million (2017-2028)
  • Figure 80: Market Size of Osteoporosis by therapies in Japan, in USD Million (2017-2028)
  • Figure 81: Market Drivers
  • Figure 82: Market Barriers
Back to Top